Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Vascular Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KLF5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLF5 Recombinant Protein (Full-Length & DNA-Binding Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9 Insect Cell / E. coli Expressed. |
View KLF5 Products |
| Gene Delivery | KLF5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and transcriptional activity assays. |
View KLF5 Products |
| Benchmark Ab | Anti-KLF5 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and ChIP assays. |
View KLF5 Products |
| Validator | KLF5 siRNA Set For knockdown verification and phenotypic target validation. |
View KLF5 Products |
| Related Target A | YAP1 Transcriptional co-activator that synergizes with KLF5 to promote tumor progression and drug resistance. |
View YAP1 Products |
| Related Target B | FBXW7 E3 ubiquitin ligase that targets KLF5 for degradation; mutations bypass KLF5 suppression. |
View FBXW7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular localization and DNA-binding complexity | High-purity recombinant KLF5 DNA-binding domain (DBD) proteins strictly verified by mass spectrometry. |
| Assay development for transcription factor inhibition | Lentivirus-based reporter systems and stable cell line development tools optimized for high-throughput screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression plasmids. |
| False Positives in Small Molecule Screens | Validated siRNA pools included for target-specific knockdown verification. |
Live KLF5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLF5 therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapy to targeted transcriptional modulation and targeted protein degradation (PROTACs). As first-generation indirect pathway inhibitors reach the clinic, the next wave of R&D is targeting direct KLF5 protein-protein interactions (PPI) and ubiquitin-proteasome system (UPS) mediated degradation pathways to treat refractory solid tumors and vascular proliferative disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Arvinas, Kymera Therapeutics, Academic Labs | Breast Cancer, Colorectal Cancer | Degradation kinetics assay (Need high-purity KLF5 protein and E3 ligase complexes) |
| Small Molecule PPI Inhibitor | Preclinical Biotech, Emory University | Gastric Cancer, Bladder Cancer | Biophysical binding assays (Need stable, sequence-verified KLF5 DBD protein) |
| RNA Therapeutics (siRNA) | Alnylam, Preclinical Consortia | Vascular Restenosis, Solid Tumors | In vitro knockdown validation (Need high-efficiency KLF5 siRNA validation sets) |